The global Single-cell omics market is anticipated to grow at a CAGR of 18.2% during the forecast period (2023-2030). Single-cell omics technologies are increasingly used in cancer research to study tumor heterogeneity and identify new therapeutic targets. As cancer incidence continues to rise, the demand for these technologies is expected to increase. Increasing collaborations between academic and industrial partners are accelerating the adoption of single-cell omics technologies in research and development. According to American Cancer Society, around 1,958,310 new cancer cases as well as 609,820 cancer deaths are estimated to occur in the U.S. in 2023. The rising technological advances in cancer diagnostic treatment methods and cancer therapies have spurred the number of new strategies such as partnership, merger and product launches. For instance, in April 2023, Bio-Techne announced a strategic partnership to develop the first fully automated spatial multiomics workflow with same-slide hyperplex detection of protein and RNA biomarkers. Designed to provide ultimate flexibility in panel design, the solution will allow researchers to easily combine well-characterized antibodies with gold-standard RNAscope in situ hybridization probes to illuminate changes in cell phenotypes and functional states across a wide range of diseases.
Browse the full report description of “Single-cell omics Market Size, Share & Trends Analysis Report by product Type (Single-Cell Genomics, Single-Cell Transcriptomics, Single-Cell Proteomics, and Single-Cell Metabolomics), by Application (Oncology, Cell Biology, Neurology, Immunology and other) and by End user (Pharmaceutical & Biotechnology Companies, Academic and Research Organizations and Hospital and Diagnostic Laboratories), Forecast Period (2023-2030)” at https://www.omrglobal.com/industry-reports/single-cell-omics-market
Further, increasing strategic initiatives by the key players and investing activities in another factor driving the growth of the market, for instance, in February 2023, BD announced a new instrument for single-cell multiomics analysis that will enable scientists to run high-throughput studies without sacrificing sample integrity potentially accelerating time to discovery across a wide range of disciplines including immunology, genetic disease research, and cancer and chronic disease research. The BD Rhapsody HT Xpress System enables scientists to isolate, barcode and analyze single cells at a high sample throughput up to eight times more cells than prior versions of BD single-cell analyzers.
Market Coverage
• The market number available for – 2022-2030
• Base year- 2022
• Forecast period- 2023-2030
• Segment Covered-
o By Product Type
o By Application
o By End User
• Regions Covered-
o North America
o Europe
o Asia-Pacific
o Rest of the World
• Competitive Landscape- includes, Becton, Dickinson and Company, Berkeley Lights Inc, BGI Genomics Co. Ltd, Danaher Corp, Dolomite Bio, Epicypher Inc., Fluidigm Corp, Illimina, Inc, Miltenyi Biotec B.V. & CO., and others.
Key questions addressed by the report
• What is the market growth rate?
• Which segment and region dominate the market in the base year?
• Which segment and region will project the fastest growth in the market?
• Who is the leader in the market?
• How are players addressing challenges to sustain growth?
• Where is the investment opportunity?
Global Single-cell omics Market Report Segment
By Product Type:
By Application:
By End user:
Global Single-cell omics Market Report Segment by Region
North America
• United States
• Canada
Europe
• UK
• Germany
• Italy
• Spain
• France
• Rest of Europe
Asia-Pacific
• China
• India
• Japan
• South Korea
• Rest of Asia-Pacific
Rest of the World
• Latin America
• Middle East & Africa
To learn more about this report request a sample copy @ https://www.omrglobal.com/request-sample/single-cell-omics-market